{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T12:09:52Z","timestamp":1773490192586,"version":"3.50.1"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Australian Government Research Training Program"},{"name":"Rachel Kierath Foundation"},{"DOI":"10.13039\/501100021954","name":"Tour de Cure","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021954","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Health and Medical Research Council of Australia","award":["APP2033152"],"award-info":[{"award-number":["APP2033152"]}]},{"DOI":"10.13039\/501100001170","name":"Cancer Council Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001170","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jerome Lejeune Foundation"},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"DOI":"10.1007\/s10555-025-10291-1","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T11:59:05Z","timestamp":1758196745000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Perspectives on the origin and therapeutic opportunities in Down syndrome-associated leukemia"],"prefix":"10.1007","volume":"44","author":[{"given":"Kunjal","family":"Panchal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence C.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishi S.","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Malinge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"issue":"1","key":"10291_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0143-7","volume":"6","author":"SE Antonarakis","year":"2020","unstructured":"Antonarakis, S. E., Skotko, B. G., Rafii, M. S., Strydom, A., Pape, S. E., Bianchi, D. W., Sherman, S. L., & Reeves, R. H. (2020). Down syndrome. Nature Reviews. Disease Primers, 6(1), Article 9. https:\/\/doi.org\/10.1038\/s41572-019-0143-7","journal-title":"Nature Reviews Disease Primers"},{"key":"10291_CR2","doi-asserted-by":"publisher","first-page":"908482","DOI":"10.3389\/fgene.2022.908482","volume":"13","author":"L Chen","year":"2022","unstructured":"Chen, L., Wang, L., Wang, Y., Hu, H., Zhan, Y., Zeng, Z., & Liu, L. (2022). Global, regional, and national burden and trends of Down syndrome from 1990 to 2019. Frontiers in Genetics, 13, 908482. https:\/\/doi.org\/10.3389\/fgene.2022.908482","journal-title":"Frontiers in Genetics"},{"issue":"11","key":"10291_CR3","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/gim.2016.23","volume":"18","author":"H Hasle","year":"2016","unstructured":"Hasle, H., Friedman, J. M., Olsen, J. H., & Rasmussen, S. A. (2016). Low risk of solid tumors in persons with Down syndrome. Genetics In Medicine, 18(11), 1151\u20131157. https:\/\/doi.org\/10.1038\/gim.2016.23","journal-title":"Genetics In Medicine"},{"key":"10291_CR4","doi-asserted-by":"publisher","unstructured":"Krivit, W., & Good, R. A. (1957). Simultaneous Occurrence of Mongolism and Leukemia: Report of a Nationwide Survey. A.M.A. Journal of Diseases of Children, 94(3), 289\u2013293. https:\/\/doi.org\/10.1001\/archpedi.1957.04030040075012","DOI":"10.1001\/archpedi.1957.04030040075012"},{"issue":"10","key":"10291_CR5","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.3324\/haematol.2023.283225","volume":"108","author":"A Baruchel","year":"2023","unstructured":"Baruchel, A., Bourquin, J.-P., Crispino, J., Cuartero, S., Hasle, H., Hitzler, J., Klusmann, J.-H., Izraeli, S., Lane, A. A., Malinge, S., Rabin, K. R., Roberts, I., Ryeom, S., Tasian, S. K., & Wagenblast, E. (2023). Down syndrome and leukemia: From basic mechanisms to clinical advances. Haematologica, 108(10), 2570\u20132581. https:\/\/doi.org\/10.3324\/haematol.2023.283225","journal-title":"Haematologica"},{"key":"10291_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/20406207241257901","author":"NR Mason","year":"2024","unstructured":"Mason, N. R., Cahill, H., Diamond, Y., McCleary, K., Kotecha, R. S., Marshall, G. M., & Mateos, M. K. (2024). Down syndrome-associated leukaemias: Current evidence and challenges. Therapeutic Advances in Hematology. https:\/\/doi.org\/10.1177\/20406207241257901","journal-title":"Therapeutic Advances in Hematology"},{"key":"10291_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0854-5","author":"AP Laurent","year":"2020","unstructured":"Laurent, A. P., Kotecha, R. S., & Malinge, S. (2020). Gain of chromosome 21 in hematological malignancies: Lessons from studying leukemia in children with Down syndrome. Leukemia. https:\/\/doi.org\/10.1038\/s41375-020-0854-5","journal-title":"Leukemia"},{"issue":"24","key":"10291_CR8","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1182\/blood-2013-07-515148","volume":"122","author":"I Roberts","year":"2013","unstructured":"Roberts, I., Alford, K., Hall, G., Juban, G., Richmond, H., Norton, A., Vallance, G., Perkins, K., Marchi, E., McGowan, S., Roy, A., Cowan, G., Anthony, M., Gupta, A., Ho, J., Uthaya, S., Curley, A., Rasiah, S. V., Watts, T., \u2026 Vyas, P. (2013). GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: Identification of a population at risk of leukemia. Blood, 122(24), 3908\u20133917. https:\/\/doi.org\/10.1182\/blood-2013-07-515148","journal-title":"Blood"},{"issue":"43","key":"10291_CR9","doi-asserted-by":"publisher","first-page":"17579","DOI":"10.1073\/pnas.1211405109","volume":"109","author":"A Roy","year":"2012","unstructured":"Roy, A., Cowan, G., Mead, A. J., Filippi, S., Bohn, G., Chaidos, A., Tunstall, Oliver, Chan, Jerry K. Y.., Choolani, Mahesh, Bennett, Phillip, Kumar, Sailesh, Atkinson, Deborah, Wyatt-Ashmead, Josephine, Hu, Ming, Stumpf, Michael P. H.., Goudevenou, Katerina, O\u2019Connor, David, Chou, Stella T.., Weiss, Mitchell J.., \u2026 Roberts, I. (2012). Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21. Proceedings of the National Academy of Sciences of the United States of America, 109(43), 17579\u201317584. https:\/\/doi.org\/10.1073\/pnas.1211405109","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"10291_CR10","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1182\/blood-2008-04-152967","volume":"112","author":"O Tunstall-Pedoe","year":"2008","unstructured":"Tunstall-Pedoe, O., Roy, A., Karadimitris, A., De La Fuente, J., Fisk, N. M., Bennett, P., Norton, A., Vyas, P., & Roberts, I. (2008). Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. Blood, 112(12), 4507\u20134511. https:\/\/doi.org\/10.1182\/blood-2008-04-152967","journal-title":"Blood"},{"issue":"43","key":"10291_CR11","doi-asserted-by":"publisher","first-page":"17573","DOI":"10.1073\/pnas.1211175109","volume":"109","author":"ST Chou","year":"2012","unstructured":"Chou, S. T., Byrska-Bishop, M., Tober, J. M., Yao, Y., VanDorn, D., Opalinska, J. B., Mills, J. A., Choi, J. K., Speck, N. A., Gadue, P., Hardison, R. C., Nemiroff, R. L., French, D. L., & Weiss, M. J. (2012). Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells. Proceedings of the National Academy of Sciences of the United States of America, 109(43), 17573\u201317578. https:\/\/doi.org\/10.1073\/pnas.1211175109","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10291_CR12","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.celrep.2016.04.031","volume":"15","author":"K Banno","year":"2016","unstructured":"Banno, K., Omori, S., Hirata, K., Nawa, N., Nakagawa, N., Nishimura, K., Ohtaka, M., Nakanishi, M., Sakuma, T., Yamamoto, T., Toki, T., Ito, E., Kokubu, C., Takeda, J., Taniguchi, H., Arahori, H., Wada, K., Kitabatake, Y., & Ozono, K. (2016). Systematic cellular disease models reveal synergistic interaction of Trisomy 21 and GATA1 mutations in hematopoietic abnormalities. Cell Reports, 15(6), 1228\u20131241. https:\/\/doi.org\/10.1016\/j.celrep.2016.04.031","journal-title":"Cell Reports"},{"key":"10291_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2025.102577","author":"K Takasaki","year":"2025","unstructured":"Takasaki, K., Wafula, E. K., Fan, J. M., Sit, Y. T., Kumar, S. S., Smith, D., Gagne, A., Gearhart, P. A., French, D. L., Thom, C. S., & Chou, S. T. (2025). Single-cell transcriptomics reveal individual and cooperative effects of trisomy 21 and GATA1s on hematopoiesis. Stem Cell Reports. https:\/\/doi.org\/10.1016\/j.stemcr.2025.102577","journal-title":"Stem Cell Reports"},{"issue":"7880","key":"10291_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41586-021-03929-x","volume":"598","author":"L Jardine","year":"2021","unstructured":"Jardine, L., Webb, S., Goh, I., Quiroga Londo\u00f1o, M., Reynolds, G., Mather, M., Olabi, B., Stephenson, E., Botting, R. A., Horsfall, D., Engelbert, J., Maunder, D., Mende, N., Murnane, C., Dann, E., McGrath, J., King, H., Kucinski, I., Queen, R., \u2026 Haniffa, M. (2021). Blood and immune development in human fetal bone marrow and Down syndrome. Nature, 598(7880), 327\u2013331. https:\/\/doi.org\/10.1038\/s41586-021-03929-x","journal-title":"Nature"},{"key":"10291_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07946-4","author":"AR Marderstein","year":"2024","unstructured":"Marderstein, A. R., De Zuani, M., Moeller, R., Bezney, J., Padhi, E. M., Wong, S., Coorens, T. H. H., Xie, Y., Xue, H., Montgomery, S. B., & Cvejic, A. (2024). Single-cell multi-omics map of human fetal blood in Down syndrome. Nature. https:\/\/doi.org\/10.1038\/s41586-024-07946-4","journal-title":"Nature"},{"key":"10291_CR16","doi-asserted-by":"publisher","unstructured":"Wagenblast, E., Ara\u00fajo, J., Gan, O. I., Cutting, S. K., Murison, A., Krivdova, G., \u2026 Lechman, E. R. (2021). Mapping the cellular origin and early evolution of leukemia in Down syndrome. Science, 373(6551), eabf6202. https:\/\/doi.org\/10.1126\/science.abf6202","DOI":"10.1126\/science.abf6202"},{"issue":"7951","key":"10291_CR17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41586-023-05736-y","volume":"615","author":"L Malle","year":"2023","unstructured":"Malle, L., Patel, R. S., Martin-Fernandez, M., Stewart, O. J., Philippot, Q., Buta, S., Richardson, Ashley, Barcessat, Vanessa, Taft, Justin, Bastard, Paul, Samuels, Julie, Mircher, Clotilde, Rebillat, Anne-Sophie., Maillebouis, Louise, Vilaire-Meunier, Marie, Tuballes, Kevin, Rosenberg, Brad R.., Trachtman, Rebecca, Casanova, Jean-Laurent., \u2026 Bogunovic, D. (2023). Autoimmunity in Down\u2019s syndrome via cytokines, CD4 T cells and CD11c+ B cells. Nature, 615(7951), 305\u2013314. https:\/\/doi.org\/10.1038\/s41586-023-05736-y","journal-title":"Nature"},{"issue":"11","key":"10291_CR18","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1016\/j.immuni.2022.09.007","volume":"55","author":"L Malle","year":"2022","unstructured":"Malle, L., Martin-Fernandez, M., Buta, S., Richardson, A., Bush, D., & Bogunovic, D. (2022). Excessive negative regulation of type I interferon disrupts viral control in individuals with Down syndrome. Immunity, 55(11), 2074-2084.e5. https:\/\/doi.org\/10.1016\/j.immuni.2022.09.007","journal-title":"Immunity"},{"key":"10291_CR19","doi-asserted-by":"publisher","first-page":"e16220","DOI":"10.7554\/eLife.16220","volume":"5","author":"KD Sullivan","year":"2016","unstructured":"Sullivan, K. D., Lewis, H. C., Hill, A. A., Pandey, A., Jackson, L. P., Cabral, J. M., Smith, K. P., Liggett, L. A., Gomez, E. B., Galbraith, M. D., DeGregori, J., & Espinosa, J. M. (2016). Trisomy 21 consistently activates the interferon response. eLife, 5, e16220. https:\/\/doi.org\/10.7554\/eLife.16220","journal-title":"eLife"},{"key":"10291_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exphem.2021.02.002","volume":"96","author":"Y Demerdash","year":"2021","unstructured":"Demerdash, Y., Kain, B., Essers, M. A. G., & King, K. Y. (2021). Yin and yang: The dual effects of interferons on hematopoiesis. Experimental Hematology, 96, 1\u201312. https:\/\/doi.org\/10.1016\/j.exphem.2021.02.002","journal-title":"Experimental Hematology"},{"key":"10291_CR21","doi-asserted-by":"publisher","unstructured":"Waugh, K. A., Araya, P., Pandey, A., Jordan, K. R., Smith, K. P., Granrath, R. E., \u2026 Espinosa, J. M. (2019). Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down Syndrome. Cell reports, 29(7), 1893\u20131908.e4. https:\/\/doi.org\/10.1016\/j.celrep.2019.10.038","DOI":"10.1016\/j.celrep.2019.10.038"},{"issue":"6","key":"10291_CR22","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41588-023-01399-7","volume":"55","author":"KA Waugh","year":"2023","unstructured":"Waugh, K. A., Minter, R., Baxter, J., Chi, C., Galbraith, M. D., Tuttle, K. D., Eduthan, Neetha P.., Kinning, Kohl T.., Andrysik, Zdenek, Araya, Paula, Dougherty, Hannah, Dunn, Lauren N.., Ludwig, Michael, Schade, Kyndal A.., Tracy, Dayna, Smith, Keith P.., Granrath, Ross E.., Busquet, Nicolas, Khanal, Santosh, \u2026 Espinosa, J. M. (2023). Triplication of the interferon receptor locus contributes to hallmarks of Down syndrome in a mouse model. Nature Genetics, 55(6), 1034\u20131047. https:\/\/doi.org\/10.1038\/s41588-023-01399-7","journal-title":"Nature Genetics"},{"key":"10291_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69822-1","volume":"10","author":"KAL Hasaart","year":"2020","unstructured":"Hasaart, K. A. L., Manders, F., van der Hoorn, M.-L., Verheul, M., Poplonski, T., Kuijk, E., de Sousa Lopes, Susana M. Chuva., & van Boxtel, R. (2020). Mutation accumulation and developmental lineages in normal and Down syndrome human fetal haematopoiesis. Scientific Reports, 10, Article 12991. https:\/\/doi.org\/10.1038\/s41598-020-69822-1","journal-title":"Scientific Reports"},{"key":"10291_CR24","doi-asserted-by":"publisher","unstructured":"Brown, A. L., De Smith, A. J., Gant, V. U., Yang, W., Scheurer, M. E., Walsh, K. M., \u2026 Rabin, K. R. (2019). Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. Blood, 134(15), 1227\u20131237.https:\/\/doi.org\/10.1182\/blood.2018890764","DOI":"10.1182\/blood.2018890764"},{"issue":"4","key":"10291_CR25","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1182\/bloodadvances.2019001216","volume":"4","author":"P Winer","year":"2020","unstructured":"Winer, P., Muskens, I. S., Walsh, K. M., Vora, A., Moorman, A. V., Wiemels, J. L., Roberts, I., Roy, A., & de Smith, A. J. (2020). Germline variants in predisposition genes in children with Down syndrome and acute lymphoblastic leukemia. Blood Advances, 4(4), 672\u2013675. https:\/\/doi.org\/10.1182\/bloodadvances.2019001216","journal-title":"Blood Advances"},{"issue":"11","key":"10291_CR26","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1038\/s41375-019-0514-9","volume":"33","author":"AJ de Smith","year":"2019","unstructured":"de Smith, A. J., Walsh, K. M., Morimoto, L. M., Francis, S. S., Hansen, H. M., Jeon, S., Gonseth, Semira, Chen, Minhui, Sun, Hanxiao, Luna-Fineman, Sandra, Antill\u00f3n, Federico, Gir\u00f3n, Ver\u00f3nica, Kang, Alice Y.., Smirnov, Ivan, Shao, Xiaorong, Whitehead, Todd P.., Barcellos, Lisa F.., Jolly, Kent W.., Healy, Jasmine, \u2026 Wiemels, J. L. (2019). Heritable variation at the chromosome 21 gene ERG is associated with acute lymphoblastic leukemia risk in children with and without Down syndrome. Leukemia, 33(11), 2746\u20132751. https:\/\/doi.org\/10.1038\/s41375-019-0514-9","journal-title":"Leukemia"},{"issue":"26","key":"10291_CR27","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1182\/blood-2014-12-580001","volume":"125","author":"T Moriyama","year":"2015","unstructured":"Moriyama, T., Relling, M. V., & Yang, J. J. (2015). Inherited genetic variation in childhood acute lymphoblastic leukemia. Blood, 125(26), 3988\u20133995. https:\/\/doi.org\/10.1182\/blood-2014-12-580001","journal-title":"Blood"},{"key":"10291_CR28","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016282","author":"Y Li","year":"2025","unstructured":"Li, Y., Elliott, N., Lein, P., Vyas, P., Roberts, I., & de Smith, A. J. (2025). Genome-wide association study of somatic GATA1s mutations in newborns with Down syndrome. Blood Advances. https:\/\/doi.org\/10.1182\/bloodadvances.2025016282","journal-title":"Blood Advances"},{"key":"10291_CR29","doi-asserted-by":"publisher","unstructured":"Marlow, E. C., Ducore, J., Kwan, M. L., Cheng, S. Y., Bowles, E. J. A., Greenlee, R. T., \u2026 Miglioretti, D. L. (2021). Leukemia Risk in a Cohort of 3.9 Million Children with and without Down Syndrome. The Journal of Pediatrics, 234, 172\u2013180.e3. https:\/\/doi.org\/10.1016\/j.jpeds.2021.03.001","DOI":"10.1016\/j.jpeds.2021.03.001"},{"issue":"9","key":"10291_CR30","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","volume":"54","author":"SW Brady","year":"2022","unstructured":"Brady, S. W., Roberts, K. G., Gu, Z., Shi, L., Pounds, S., Pei, D., Cheng, C., Dai, Y., Devidas, M., Qu, C., Hill, A. N., Payne-Turner, D., Ma, X., Iacobucci, I., Baviskar, P., Wei, L., Arunachalam, S., Hagiwara, K., Liu, Y., \u2026 Mullighan, C. (2022). The genomic landscape of pediatric acute lymphoblastic leukemia. Nature Genetics, 54(9), 1376\u20131389. https:\/\/doi.org\/10.1038\/s41588-022-01159-z","journal-title":"Nature Genetics"},{"issue":"5","key":"10291_CR31","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/bjh.13096","volume":"167","author":"I Roberts","year":"2014","unstructured":"Roberts, I., & Izraeli, S. (2014). Haematopoietic development and leukaemia in Down syndrome. British Journal of Haematology, 167(5), 587\u2013599. https:\/\/doi.org\/10.1111\/bjh.13096","journal-title":"British Journal of Haematology"},{"issue":"12","key":"10291_CR32","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1182\/blood-2008-11-163501","volume":"113","author":"S Malinge","year":"2009","unstructured":"Malinge, S., Izraeli, S., & Crispino, J. D. (2009). Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood, 113(12), 2619\u20132628. https:\/\/doi.org\/10.1182\/blood-2008-11-163501","journal-title":"Blood"},{"issue":"11","key":"10291_CR33","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.1182\/blood-2003-01-0013","volume":"101","author":"JK Hitzler","year":"2003","unstructured":"Hitzler, J. K., Cheung, J., Li, Y., Scherer, S. W., & Zipursky, A. (2003). GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood, 101(11), 4301\u20134304. https:\/\/doi.org\/10.1182\/blood-2003-01-0013","journal-title":"Blood"},{"issue":"5","key":"10291_CR34","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1182\/blood-2004-04-1563","volume":"104","author":"JW Taub","year":"2004","unstructured":"Taub, J. W., Mundschau, G., Ge, Y., Poulik, J. M., Qureshi, F., Jensen, T., James, S. Jill., Matherly, Larry H.., Wechsler, Joshua, & Crispino, J. D. (2004). Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood, 104(5), 1588\u20131589. https:\/\/doi.org\/10.1182\/blood-2004-04-1563","journal-title":"Blood"},{"issue":"1","key":"10291_CR35","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/ng955","volume":"32","author":"J Wechsler","year":"2002","unstructured":"Wechsler, J., Greene, M., McDevitt, M. A., Anastasi, J., Karp, J. E., Le Beau, M. M., & Crispino, J. D. (2002). Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nature Genetics, 32(1), 148\u2013152. https:\/\/doi.org\/10.1038\/ng955","journal-title":"Nature Genetics"},{"key":"10291_CR36","doi-asserted-by":"publisher","unstructured":"Elliott, N., Bhatnagar, N., Buck, G., Cruz Hernandez, D., Perkins, K., de Smith, A. J., \u2026 Roberts, I. (2025). Clinical significance of preleukemic somatic GATA1 mutations in children with Down syndrome. Blood, blood.2025029250. https:\/\/doi.org\/10.1182\/blood.2025029250","DOI":"10.1182\/blood.2025029250"},{"issue":"26","key":"10291_CR37","doi-asserted-by":"publisher","first-page":"6752","DOI":"10.1182\/blood-2011-04-350017","volume":"118","author":"AS Gamis","year":"2011","unstructured":"Gamis, A. S., Alonzo, T. A., Gerbing, R. B., Hilden, J. M., Sorrell, A. D., Sharma, M., Loew, Thomas W.., Arceci, Robert J.., Barnard, Dorothy, Doyle, John, Massey, Gita, Perentesis, John, Ravindranath, Yaddanapudi, Taub, Jeffrey, & Smith, F. O. (2011). Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: A report from the Children\u2019s Oncology Group Study A2971. Blood, 118(26), 6752\u20136759. https:\/\/doi.org\/10.1182\/blood-2011-04-350017","journal-title":"Blood"},{"issue":"8","key":"10291_CR38","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1172\/JCI40609","volume":"123","author":"AJ Woo","year":"2013","unstructured":"Woo, A. J., Wieland, K., Huang, H., Akie, T. E., Piers, T., Kim, J., & Cantor, A. B. (2013). Developmental differences in IFN signaling affect GATA1s-induced megakaryocyte hyperproliferation. Journal of Clinical Investigation, 123(8), 3292\u20133304. https:\/\/doi.org\/10.1172\/JCI40609","journal-title":"Journal of Clinical Investigation"},{"issue":"9199","key":"10291_CR39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0140-6736(99)05264-2","volume":"355","author":"H Hasle","year":"2000","unstructured":"Hasle, H., Clemmensen, I. H., & Mikkelsen, M. (2000). Risks of leukaemia and solid tumours in individuals with Down\u2019s syndrome. The Lancet, 355(9199), 165\u2013169. https:\/\/doi.org\/10.1016\/S0140-6736(99)05264-2","journal-title":"The Lancet"},{"issue":"20","key":"10291_CR40","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, Clara D.., Cazzola, Mario, & Vardiman, J. W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"issue":"25","key":"10291_CR41","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1182\/blood-2017-01-764324","volume":"129","author":"JW Taub","year":"2017","unstructured":"Taub, J. W., Berman, J. N., Hitzler, J. K., Sorrell, A. D., Lacayo, N. J., Mast, K., Head, D., Raimondi, S., Hirsch, B., Ge, Y., Gerbing, R. B., Wang, Y.-C., Alonzo, T. A., Campana, D., Coustan-Smith, E., Mathew, P., & Gamis, A. S. (2017). Improved outcomes for myeloid leukemia of Down syndrome: A report from the Children\u2019s Oncology Group AAML0431 trial. Blood, 129(25), 3304\u20133313. https:\/\/doi.org\/10.1182\/blood-2017-01-764324","journal-title":"Blood"},{"issue":"9","key":"10291_CR42","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2012-03-414755","volume":"120","author":"T Taga","year":"2012","unstructured":"Taga, T., Saito, A. M., Kudo, K., Tomizawa, D., Terui, K., Moritake, H., Kinoshita, A., Iwamoto, S., Nakayama, H., Takahashi, H., Tawa, A., Shimada, A., Taki, T., Kigasawa, H., Koh, K., & Adachi, S. (2012). Clinical characteristics and outcome of refractory\/relapsed myeloid leukemia in children with Down syndrome. Blood, 120(9), 1810\u20131815. https:\/\/doi.org\/10.1182\/blood-2012-03-414755","journal-title":"Blood"},{"issue":"21","key":"10291_CR43","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.1182\/bloodadvances.2022009381","volume":"7","author":"N Raghuram","year":"2023","unstructured":"Raghuram, N., Hasegawa, D., Nakashima, K., Rahman, S., Antoniou, E., Skajaa, T., Merli, P., Verma, A., Rabin, K. R., Aftandilian, C., Kotecha, R. S., Cheuk, D., Jahnukainen, K., Kolenova, A., Balwierz, W., Norton, A., O\u2019Brien, M., Cellot, S., Chopek, A., \u2026 Hitzler, J. (2023). Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome. Blood Advances, 7(21), 6532\u20136539. https:\/\/doi.org\/10.1182\/bloodadvances.2022009381","journal-title":"Blood Advances"},{"issue":"1","key":"10291_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2009.07789.x","volume":"147","author":"A Roy","year":"2009","unstructured":"Roy, A., Roberts, I., Norton, A., & Vyas, P. (2009). Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: A multi-step model of myeloid leukaemogenesis. British Journal of Haematology, 147(1), 3\u201312. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07789.x","journal-title":"British Journal of Haematology"},{"key":"10291_CR45","doi-asserted-by":"publisher","unstructured":"Trinh, M. K., Schuschel, K., Issa, H., Thomas, R., Parks, C., Oszlanczi, A., \u2026 Behjati, S. (2025, April 3). Single cell transcriptional evolution of myeloid leukaemia of Down syndrome. bioRxiv. https:\/\/doi.org\/10.1101\/2025.04.01.646181","DOI":"10.1101\/2025.04.01.646181"},{"issue":"14","key":"10291_CR46","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1182\/blood-2013-05-503011","volume":"122","author":"S Malinge","year":"2013","unstructured":"Malinge, S., Chlon, T., Dor\u00e9, L. C., Ketterling, R. P., Tallman, M. S., Paietta, E., Gamis, A. S., Taub, J. W., Chou, S. T., Weiss, M. J., Crispino, J. D., & Figueroa, M. E. (2013). Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes. Blood, 122(14), e33\u2013e43. https:\/\/doi.org\/10.1182\/blood-2013-05-503011","journal-title":"Blood"},{"key":"10291_CR47","doi-asserted-by":"publisher","unstructured":"Labuhn, M., Perkins, K., Matzk, S., Varghese, L., Garnett, C., Papaemmanuil, E., \u2026 Klusmann, J.-H. (2019). Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. Cancer Cell, 36(2), 123\u2013138.e10. https:\/\/doi.org\/10.1016\/j.ccell.2019.06.007","DOI":"10.1016\/j.ccell.2019.06.007"},{"issue":"11","key":"10291_CR48","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/ng.2759","volume":"45","author":"K Yoshida","year":"2013","unstructured":"Yoshida, K., Toki, T., Okuno, Y., Kanezaki, R., Shiraishi, Y., Sato-Otsubo, A., Sanada, M., Park, M.-j, Terui, K., Suzuki, H., Kon, A., Nagata, Y., Sato, Y., Wang, RuNan, Shiba, N., Chiba, K., Tanaka, H., Hama, A., Muramatsu, H., \u2026 Ogawa, S. (2013). The landscape of somatic mutations in Down syndrome\u2013related myeloid disorders. Nature Genetics, 45(11), 1293\u20131299. https:\/\/doi.org\/10.1038\/ng.2759","journal-title":"Nature Genetics"},{"issue":"25","key":"10291_CR49","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1182\/blood.2023022247","volume":"143","author":"T Sato","year":"2024","unstructured":"Sato, T., Yoshida, K., Toki, T., Kanezaki, R., Terui, K., Saiki, R., Ojima, M., Ochi, Y., Mizuno, S., Yoshihara, M., Uechi, T., Kenmochi, N., Tanaka, S., Matsubayashi, J., Kisai, K., Kudo, Ko., Yuzawa, K., Takahashi, Y., Tanaka, T., \u2026 Ito, E. (2024). Landscape of driver mutations and their clinical effects on Down syndrome-related myeloid neoplasms. Blood, 143(25), 2627\u20132643. https:\/\/doi.org\/10.1182\/blood.2023022247","journal-title":"Blood"},{"issue":"10","key":"10291_CR50","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1182\/blood.2022017619","volume":"141","author":"S Gialesaki","year":"2023","unstructured":"Gialesaki, S., Br\u00e4uer-Hartmann, D., Issa, H., Bhayadia, R., Alejo-Valle, O., Verboon, L., Schmell, A.-L., Laszig, S., Reg\u00e9nyi, E., Schuschel, K., Labuhn, M., Ng, M., Winkler, R., Ihling, C., Sinz, A., Gla\u00df, M., H\u00fcttelmaier, S., Matzk, S., Schmid, L., \u2026 Klusmann, J.-H. (2023). RUNX1 isoform disequilibrium promotes the development of trisomy 21\u2013associated myeloid leukemia. Blood, 141(10), 1105\u20131118. https:\/\/doi.org\/10.1182\/blood.2022017619","journal-title":"Blood"},{"issue":"15","key":"10291_CR51","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1101\/gad.1903410","volume":"24","author":"J-H Klusmann","year":"2010","unstructured":"Klusmann, J.-H., Godinho, F. J., Heitmann, K., Maroz, A., Koch, M. L., Reinhardt, D., Lee Koch, M., Orkin, S. H., & Li, Z. (2010). Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes & Development, 24(15), 1659\u20131672. https:\/\/doi.org\/10.1101\/gad.1903410","journal-title":"Genes & Development"},{"issue":"6","key":"10291_CR52","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/ng1566","volume":"37","author":"Z Li","year":"2005","unstructured":"Li, Z., Godinho, F. J., Klusmann, J.-H., Garriga-Canut, M., Yu, C., & Orkin, S. H. (2005). Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nature Genetics, 37(6), 613\u2013619. https:\/\/doi.org\/10.1038\/ng1566","journal-title":"Nature Genetics"},{"key":"10291_CR53","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.172851","author":"YT Sit","year":"2023","unstructured":"Sit, Y. T., Takasaki, K., An, H. H., Xiao, Y., Hurtz, C., Gearhart, P., Gearhart, P. A., Zhang, Z., Gadue, P., French, D. L., & Chou, S. T. (2023). Synergistic roles of DYRK1A and GATA1 in trisomy 21 megakaryopoiesis. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.172851","journal-title":"JCI Insight"},{"issue":"13","key":"10291_CR54","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/bloodadvances.2018018945","volume":"2","author":"M Flasinski","year":"2018","unstructured":"Flasinski, M., Scheibke, K., Zimmermann, M., Creutzig, U., Reinhardt, K., Verwer, F., de Haas, V., van der Velden, V. H. J., von Neuhoff, C., Zwaan, C. M., Reinhardt, D., & Klusmann, J.-H. (2018). Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD prevention 2007 study. Blood Advances, 2(13), 1532\u20131540. https:\/\/doi.org\/10.1182\/bloodadvances.2018018945","journal-title":"Blood Advances"},{"issue":"5","key":"10291_CR55","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1038\/s41375-021-01171-y","volume":"35","author":"G Yamato","year":"2021","unstructured":"Yamato, G., Deguchi, T., Terui, K., Toki, T., Watanabe, T., Imaizumi, T., Hama, A., Iwamoto, S., Hasegawa, D., Ueda, T., Yokosuka, T., Tanaka, S., Yanagisawa, R., Koh, K., Saito, A. M., Horibe, K., Hayashi, Y., Adachi, S., Mizutani, S., \u2026 Muramatsu, H. (2021). Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome. Leukemia, 35(5), 1480\u20131484. https:\/\/doi.org\/10.1038\/s41375-021-01171-y","journal-title":"Leukemia"},{"issue":"9","key":"10291_CR56","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1038\/s41375-021-01157-w","volume":"35","author":"T Taga","year":"2021","unstructured":"Taga, T., Tanaka, S., Hasegawa, D., Terui, K., Toki, T., Iwamoto, S., Hiramatsu, H., Miyamura, T., Hashii, Y., Moritake, H., Nakayama, H., Takahashi, H., Shimada, A., Taki, T., Ito, E., Hama, A., Ito, M., Koh, K., Saito, A. M., \u2026 Tomizawa, D. (2021). Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome. Leukemia, 35(9), 2508\u20132516. https:\/\/doi.org\/10.1038\/s41375-021-01157-w","journal-title":"Leukemia"},{"issue":"1","key":"10291_CR57","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1182\/blood-2013-06-509463","volume":"123","author":"TD Buitenkamp","year":"2014","unstructured":"Buitenkamp, T. D., Izraeli, S., Zimmermann, M., Forestier, E., Heerema, N. A., van den Heuvel-Eibrink, M. M., Pieters, R., Korbijn, C. M., Silverman, L. B., Schmiegelow, K., Liang, D.-C., Horibe, K., Arico, M., Biondi, A., Basso, G., Rabin, K. R., Schrappe, M., Cario, G., Mann, G., \u2026 Zwaan, C. M. (2014). Acute lymphoblastic leukemia in children with Down syndrome: A retrospective analysis from the Ponte di Legno study group. Blood, 123(1), 70\u201377. https:\/\/doi.org\/10.1182\/blood-2013-06-509463","journal-title":"Blood"},{"key":"10291_CR58","doi-asserted-by":"publisher","unstructured":"Li, Z., Chang, T.-C., Junco, J. J., Devidas, M., Li, Y., Yang, W., \u2026 Yang, J. J. (2023). Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia. Blood. https:\/\/doi.org\/10.1182\/blood.2023019765","DOI":"10.1182\/blood.2023019765"},{"issue":"2","key":"10291_CR59","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1200\/JCO.23.00389","volume":"42","author":"KR Rabin","year":"2024","unstructured":"Rabin, K. R., Devidas, M., Chen, Z., Ji, L., Kairalla, J., Hitzler, J. K., Yang, J. J., Carroll, A. J., Heerema, N. A., Borowitz, M. J., Wood, B. L., Roberts, K. G., Mullighan, C. G., Harvey, R. C., Chen, I.-M., Willman, C. L., Reshmi, S. C., Gastier-Foster, J. M., Bhojwani, D., \u2026 Angiolillo, A. L. (2024). Outcomes in children, adolescents, and young adults with Down syndrome and ALL: A report from the Children\u2019s Oncology Group. Journal of Clinical Oncology, 42(2), 218\u2013227. https:\/\/doi.org\/10.1200\/JCO.23.00389","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10291_CR60","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1001\/jamaoncol.2023.2163","volume":"9","author":"A Verma","year":"2023","unstructured":"Verma, A., Lupo, P. J., Shah, N. N., Hitzler, J., & Rabin, K. R. (2023). Management of down syndrome-associated leukemias: A review. JAMA Oncology, 9(9), 1283\u20131290. https:\/\/doi.org\/10.1001\/jamaoncol.2023.2163","journal-title":"JAMA Oncology"},{"issue":"4","key":"10291_CR61","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/08880018.2017.1363837","volume":"34","author":"J Zawitkowska","year":"2017","unstructured":"Zawitkowska, J., Od\u00f3j, T., Drabko, K., Zaucha-Pra\u017cmo, A., Rudnicka, J., Romiszewski, M., Matysiak, M., Kwieci\u0144ska, K., \u0106wikli\u0144ska, M., Balwierz, W., Owoc-Lempach, J., Derwich, K., Wachowiak, J., Nied\u017awiecki, M., Adamkiewicz- Dro\u017cy\u0144ska, E., Treli\u0144ska, J., M\u0142ynarski, W., Ko\u0142tan, A., Wysocki, M., \u2026 Kowalczyk, J. (2017). Outcome of acute lymphoblastic leukemia in children with Down syndrome\u2014Polish pediatric leukemia and lymphoma study group report. Pediatric Hematology and Oncology, 34(4), 199\u2013205. https:\/\/doi.org\/10.1080\/08880018.2017.1363837","journal-title":"Pediatric Hematology and Oncology"},{"issue":"9648","key":"10291_CR62","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/S0140-6736(08)61341-0","volume":"372","author":"D Bercovich","year":"2008","unstructured":"Bercovich, D., Ganmore, I., Scott, L. M., Wainreb, G., Birger, Y., Elimelech, A., Shochat, C., Cazzaniga, G., Biondi, A., Basso, G., Cario, G., Schrappe, M., Stanulla, M., Strehl, S., Haas, O. A., Mann, G., Binder, V., Borkhardt, A., Kempski, H., \u2026 Izraeli, S. (2008). Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down\u2019s syndrome. The Lancet, 372(9648), 1484\u20131492. https:\/\/doi.org\/10.1016\/S0140-6736(08)61341-0","journal-title":"The Lancet"},{"issue":"5","key":"10291_CR63","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1182\/blood-2009-08-235408","volume":"115","author":"L Hertzberg","year":"2010","unstructured":"Hertzberg, L., Vendramini, E., Ganmore, I., Cazzaniga, G., Schmitz, M., Chalker, J., Shiloh, R., Iacobucci, I., Shochat, C., Zeligson, S., Cario, G., Stanulla, M., Strehl, S., Russell, L. J., Harrison, C. J., Bornhauser, B., Yoda, A., Rechavi, G., Bercovich, D., \u2026 Izraeli, S. (2010). Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: A report from the International BFM Study Group. Blood, 115(5), 1006\u20131017. https:\/\/doi.org\/10.1182\/blood-2009-08-235408","journal-title":"Blood"},{"issue":"10","key":"10291_CR64","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1111\/cas.14160","volume":"110","author":"Y Kubota","year":"2019","unstructured":"Kubota, Y., Uryu, K., Ito, T., Seki, M., Kawai, T., Isobe, T., Kumagai, T., Toki, T., Yoshida, K., Suzuki, H., Kataoka, K., Shiraishi, Y., Chiba, K., Tanaka, H., Ohki, K., Kiyokawa, N., Kagawa, J., Miyano, S., Oka, A., \u2026 Takita, J. (2019). Integrated genetic and epigenetic analysis revealed heterogeneity of acute lymphoblastic leukemia in Down syndrome. Cancer Science, 110(10), 3358\u20133367. https:\/\/doi.org\/10.1111\/cas.14160","journal-title":"Cancer Science"},{"key":"10291_CR65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3519","author":"AP Laurent","year":"2020","unstructured":"Laurent, A. P., Siret, A., Ignacimouttou, C., Panchal, K., Diop, M., Jenni, S., Tsai, Y.-C., Roos-Weil, D., Aid, Z., Prade, N., Lagarde, S., Plassard, D., Pierron, G., Daudigeos, E., Lecluse, Y., Droin, N., Bornhauser, B. C., Cheung, L. C., Crispino, J. D., \u2026 Malinge, S. (2020). Constitutive activation of RAS\/MAPK pathway cooperates with trisomy 21 and is therapeutically exploitable in Down syndrome B-cell leukemia. Clinical Cancer Research. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3519","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10291_CR66","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1038\/ncomms5654","volume":"5","author":"SI Nikolaev","year":"2014","unstructured":"Nikolaev, S. I., Garieri, M., Santoni, F., Falconnet, E., Ribaux, P., Guipponi, M., Murray, A., Groet, J., Giarin, E., Basso, G., Nizetic, D., & Antonarakis, S. E. (2014). Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations. Nature Communications, 5(1), 4654. https:\/\/doi.org\/10.1038\/ncomms5654","journal-title":"Nature Communications"},{"issue":"20","key":"10291_CR67","doi-asserted-by":"publisher","first-page":"E4030","DOI":"10.1073\/pnas.1702489114","volume":"114","author":"O Schwartzman","year":"2017","unstructured":"Schwartzman, O., Savino, A. M., Gombert, M., Palmi, C., Cario, G., Schrappe, M., Eckert, C., von Stackelberg, A., Huang, J.-Y., Hameiri-Grossman, M., Avigad, S., te Kronnie, G., Geron, I., Birger, Y., Rein, A., Zarfati, G., Fischer, U., Mukamel, Z., Stanulla, M., \u2026 Izraeli, S. (2017). Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome. Proceedings of the National Academy of Sciences of the United States of America, 114(20), E4030\u2013E4039. https:\/\/doi.org\/10.1073\/pnas.1702489114","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10291_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02602-w","author":"C-J Hsu","year":"2025","unstructured":"Hsu, C.-J., Schraw, J. M., Desrosiers, T. A., Janitz, A. E., Kirby, R. S., Nestoridi, E., Nembhard, W. N., Salemi, J. L., Shumate, C., Tanner, J. P., Yazdy, M. M., Scheurer, M. E., Rabin, K. R., & Lupo, P. J. (2025). All genetic subtypes of B-cell acute lymphoblastic leukemia exhibit increased incidence rates in children with Down syndrome. Leukemia. https:\/\/doi.org\/10.1038\/s41375-025-02602-w","journal-title":"Leukemia"},{"issue":"3","key":"10291_CR69","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/leu.2009.231","volume":"24","author":"E Chapiro","year":"2010","unstructured":"Chapiro, E., Russell, L., Lainey, E., Kaltenbach, S., Ragu, C., Della-Valle, V., Hanssens, K., Macintyre, E. A., Radford-Weiss, I., Delabesse, E., Cav\u00e9, H., Mercher, T., Harrison, C. J., Nguyen-Khac, F., Dubreuil, P., & Bernard, O. A. (2010). Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. Leukemia, 24(3), 642\u2013645. https:\/\/doi.org\/10.1038\/leu.2009.231","journal-title":"Leukemia"},{"issue":"11","key":"10291_CR70","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/ng.469","volume":"41","author":"CG Mullighan","year":"2009","unstructured":"Mullighan, C. G., Collins-Underwood, J. R., Phillips, L. A. A., Loudin, M. G., Liu, W., Zhang, J., Ma, J., Coustan-Smith, E., Harvey, R. C., Willman, C. L., Mikhail, F. M., Meyer, J., Carroll, A. J., Williams, R. T., Cheng, J., Heerema, N. A., Basso, G., Pession, A., Pui, C.-H., \u2026 Rabin, K. R. (2009). Rearrangement of CRLF2 in B-progenitor\u2013 and Down syndrome\u2013associated acute lymphoblastic leukemia. Nature Genetics, 41(11), 1243\u20131246. https:\/\/doi.org\/10.1038\/ng.469","journal-title":"Nature Genetics"},{"issue":"5","key":"10291_CR71","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/gcc.22439","volume":"56","author":"LJ Russell","year":"2017","unstructured":"Russell, L. J., Jones, L., Enshaei, A., Tonin, S., Ryan, S. L., Eswaran, J., Nakjang, S., Papaemmanuil, E., Tubio, J. M. C., Fielding, A. K., Vora, A., Campbell, P. J., Moorman, A. V., & Harrison, C. J. (2017). Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia. Genes, Chromosomes & Cancer, 56(5), 363\u2013372. https:\/\/doi.org\/10.1002\/gcc.22439","journal-title":"Genes, Chromosomes & Cancer"},{"key":"10291_CR72","doi-asserted-by":"publisher","first-page":"100223","DOI":"10.1016\/j.ejcped.2025.100223","volume":"5","author":"N Michels","year":"2025","unstructured":"Michels, N., Admiraal, J., Boeree, A., Sonneveld, E., Moorman, A. V., Escherich, G., Sutton, R., Beverloo, H. B., Pieters, R., Zwaan, C. M., den Boer, M. L., & Boer, J. M. (2025). IGH rearrangements in Down syndrome acute lymphoblastic leukemia. EJC Paediatric Oncology, 5, 100223. https:\/\/doi.org\/10.1016\/j.ejcped.2025.100223","journal-title":"EJC Paediatric Oncology"},{"issue":"6","key":"10291_CR73","doi-asserted-by":"publisher","first-page":"e892","DOI":"10.1097\/HS9.0000000000000892","volume":"7","author":"C Palmi","year":"2023","unstructured":"Palmi, C., Bresolin, S., Junk, S., Fazio, G., Silvestri, D., Zaliova, M., Oikonomou, A., Scharov, K., Stanulla, M., Moericke, A., Zimmermann, M., Schrappe, M., Buldini, B., Bhatia, S., Borkhardt, A., Saitta, C., Galbiati, M., Bardini, M., Lo Nigro, L., \u2026 Cazzaniga, G. (2023). Definition and prognostic value of Ph-like and IKZF1plus status in children with Down syndrome and B-cell precursor acute lymphoblastic leukemia. HemaSphere, 7(6), e892. https:\/\/doi.org\/10.1097\/HS9.0000000000000892","journal-title":"HemaSphere"},{"issue":"12","key":"10291_CR74","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","volume":"36","author":"M Stanulla","year":"2018","unstructured":"Stanulla, M., Dagdan, E., Zaliova, M., M\u00f6ricke, A., Palmi, C., Cazzaniga, G., Eckert, C., te Kronnie, G., Bourquin, J.-P., Bornhauser, B., Koehler, R., Bartram, C. R., Ludwig, W.-D., Bleckmann, K., Groeneveld-Krentz, S., Schewe, D., Junk, S. V., Hinze, L., Klein, N., \u2026 International BFM Study Group. (2018). IKZF1plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia. Journal of Clinical Oncology, 36(12), 1240\u20131249. https:\/\/doi.org\/10.1200\/JCO.2017.74.3617","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10291_CR75","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41388-020-01567-7","volume":"40","author":"D Koschut","year":"2021","unstructured":"Koschut, D., Ray, D., Li, Z., Giarin, E., Groet, J., Ali\u0107, I., Kham, S.-Y., Chng, W. J., Ariffin, H., Weinstock, D. M., Yeoh, A.-J., Basso, G., & Ni\u017eeti\u0107, D. (2021). RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia. Oncogene, 40(4), 746\u2013762. https:\/\/doi.org\/10.1038\/s41388-020-01567-7","journal-title":"Oncogene"},{"issue":"23","key":"10291_CR76","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1182\/blood.2021012206","volume":"138","author":"J Hitzler","year":"2021","unstructured":"Hitzler, J., Alonzo, T., Gerbing, R., Beckman, A., Hirsch, B., Raimondi, S., Chisholm, K., Viola, S., Brodersen, L., Loken, M., Tong, S., Druley, T., O\u2019Brien, M., Hijiya, N., Heerema-McKenney, A., Wang, Y.-C., Shore, R., Taub, J., Gamis, A., \u2026 Berman, J. N. (2021). High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: Results of the COG AAML1531 trial. Blood, 138(23), 2337\u20132346. https:\/\/doi.org\/10.1182\/blood.2021012206","journal-title":"Blood"},{"key":"10291_CR77","doi-asserted-by":"crossref","unstructured":"Hitzler, J. (2024). Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children\u2019s Oncology Group. Presented at the 66th ASH Annual Meeting, ASH. Retrieved from https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper202621.html","DOI":"10.1182\/blood-2024-202621"},{"issue":"9","key":"10291_CR78","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31141","volume":"71","author":"M Miladinovic","year":"2024","unstructured":"Miladinovic, M., Reinhardt, D., Hasle, H., Goemans, B. F., Tomizawa, D., Hitzler, J., & Klusmann, J.-H. (2024). Guideline for treating relapsed or refractory myeloid leukemia in children with Down syndrome. Pediatric Blood & Cancer, 71(9), Article e31141. https:\/\/doi.org\/10.1002\/pbc.31141","journal-title":"Pediatric Blood & Cancer"},{"key":"10291_CR79","doi-asserted-by":"publisher","first-page":"102546","DOI":"10.1016\/j.coph.2025.102546","volume":"83","author":"CC Smith","year":"2025","unstructured":"Smith, C. C., & Tasian, S. K. (2025). Precision medicine and immunotherapeutic approaches for relapsed\/refractory paediatric acute myeloid leukaemia. Current Opinion in Pharmacology, 83, 102546. https:\/\/doi.org\/10.1016\/j.coph.2025.102546","journal-title":"Current Opinion in Pharmacology"},{"key":"10291_CR80","doi-asserted-by":"publisher","unstructured":"Gupta, S., Rau, R. E., Kairalla, J. A., Rabin, K. R., Wang, C., Angiolillo, A. L., \u2026 Loh, M. L. (2025). Blinatumomab in standard risk pediatric B-acute lymphoblastic leukemia. The New England journal of medicine, 392(9), 875\u2013891. https:\/\/doi.org\/10.1056\/NEJMoa2411680","DOI":"10.1056\/NEJMoa2411680"},{"key":"10291_CR81","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1182\/blood-2021-148967","volume":"138","author":"AM Li","year":"2021","unstructured":"Li, A. M., Rabin, K. R., Kairalla, J., Wang, C., Devidas, M., Militano, O., Okada, M., Hitzler, J. K., Angiolillo, A. L., Raetz, E. A., Loh, M. L., Gupta, S., & Rau, R. E. (2021). Blinatumomab associated seizure risk in patients with Down syndrome and B-lymphoblastic leukemia: An interim report from Children\u2019s Oncology Group (COG) study AALL1731. Blood, 138, 2304. https:\/\/doi.org\/10.1182\/blood-2021-148967","journal-title":"Blood"},{"key":"10291_CR82","unstructured":"Hodder, A., Kirkwood, A., van der Sluis, I. M., Mondelaers, V., Segers, H., Escherich, G., \u2026 Samarasinghe, S. (2024). Blinatumomab for first linie treatment in intermediate and high risk down syndrome B-cell acute lymphoblastic leukaemia: initial findings from the ALLTogether1 DS TRIAL. Presented at the EHA 2024, Madrid, Spain. Retrieved from https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/422215\/sujith.samarasinghe.blinatumomab.for.first.line.treatment.in.intermediate.and.html?f=listing%3D1%2Abrowseby%3D8%2Asortby%3D2%2Ace_id%3D2552%2Aot_id%3D29190%2Amarker%3D5099"},{"issue":"17","key":"10291_CR83","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","volume":"388","author":"IM van der Sluis","year":"2023","unstructured":"van der Sluis, I. M., de Lorenzo, P., Kotecha, R. S., Attarbaschi, A., Escherich, G., Nysom, K., Stary, J., Ferster, A., Brethon, B., Locatelli, F., Schrappe, M., van Scholte- Houtem, P. E., Valsecchi, M. G., & Pieters, R. (2023). Blinatumomab added to chemotherapy in infant lymphoblastic leukemia. New England Journal of Medicine, 388(17), 1572\u20131581. https:\/\/doi.org\/10.1056\/NEJMoa2214171","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10291_CR84","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.bbmt.2013.02.017","volume":"19","author":"JK Hitzler","year":"2013","unstructured":"Hitzler, J. K., He, W., Doyle, J., Cairo, M., Camitta, B. M., Chan, K. W., Diaz Perez, M. A., Fraser, C., Gross, T. G., Horan, J. T., Kennedy-Nasser, A. A., Kitko, C., Kurtzberg, J., Lehmann, L., O\u2019Brien, T., Pulsipher, M. A., Smith, F. O., Zhang, M.-J., Eapen, M., & Carpenter, P. A. (2013). Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome. Biology of Blood and Marrow Transplantation, 19(6), 893\u2013897. https:\/\/doi.org\/10.1016\/j.bbmt.2013.02.017","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"1","key":"10291_CR85","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/bjh.12348","volume":"162","author":"F Meyr","year":"2013","unstructured":"Meyr, F., Escherich, G., Mann, G., Klingebiel, T., Kulozik, A., Rossig, C., Schrappe, M., Henze, G., von Stackelberg, A., & Hitzler, J. (2013). Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome. British Journal of Haematology, 162(1), 98\u2013106. https:\/\/doi.org\/10.1111\/bjh.12348","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10291_CR86","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/s41375-022-01550-z","volume":"36","author":"TW Laetsch","year":"2022","unstructured":"Laetsch, T. W., Maude, S. L., Balduzzi, A., Rives, S., Bittencourt, H., Boyer, M. W., Buechner, J., De Moerloose, B., Qayed, M., Phillips, C. L., Pulsipher, M. A., Hiramatsu, H., Tiwari, R., & Grupp, S. A. (2022). Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed\/refractory acute lymphoblastic leukemia. Leukemia, 36(6), 1508\u20131515. https:\/\/doi.org\/10.1038\/s41375-022-01550-z","journal-title":"Leukemia"},{"key":"10291_CR87","doi-asserted-by":"publisher","unstructured":"Pacenta, H., Schultz, L., Baggott, C., Shah, N., Prabhu, S., Phillips, C., \u2026 Laetsch, T. (2021). Real world treatment of pediatric patients with down syndrome and relapsed\/refractory (R\/R) B-cell acute lymphoblastic leukemia (B-All) treated with tisagenlecleucel. In Pediatric Blood and Cancer (Vol. 68, pp. S87\u2013S88). Presented at the 53rd Congress of the International Society of Paediatric Oncology (SIOP), Virtual: Wiley Periodicals, Inc. https:\/\/doi.org\/10.1002\/pbc.29349","DOI":"10.1002\/pbc.29349"},{"issue":"4","key":"10291_CR88","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","volume":"33","author":"D Bhojwani","year":"2019","unstructured":"Bhojwani, D., Sposto, R., Shah, N. N., Rodriguez, V., Yuan, C., Stetler-Stevenson, M., O\u2019Brien, M. M., McNeer, J. L., Quereshi, A., Cabannes, A., Schlegel, P., Rossig, C., Dalla-Pozza, L., August, K., Alexander, S., Bourquin, J.-P., Zwaan, M., Raetz, E. A., Loh, M. L., & Rheingold, S. R. (2019). Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. Leukemia, 33(4), 884\u2013892. https:\/\/doi.org\/10.1038\/s41375-018-0265-z","journal-title":"Leukemia"},{"key":"10291_CR89","doi-asserted-by":"publisher","unstructured":"O\u2019Brien, M. M., Ji, L., Shah, N. N., Rheingold, S. R., Bhojwani, D., Yuan, C. M., \u2026 Loh, M. L. (2022). Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children\u2019s Oncology Group Protocol AALL1621. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 40(9), 956\u2013967. https:\/\/doi.org\/10.1200\/JCO.21.01693","DOI":"10.1200\/JCO.21.01693"},{"key":"10291_CR90","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-024-03890-1","author":"A Kohso","year":"2024","unstructured":"Kohso, A., Toyoda, H., Hanaki, R., Niwa, K., Okumura, Y., Morimoto, M., Ito, T., & Hirayama, M. (2024). Inotuzumab ozogamicin for relapse prevention in a boy with Down syndrome and relapsed acute lymphoblastic leukemia. International Journal of Hematology. https:\/\/doi.org\/10.1007\/s12185-024-03890-1","journal-title":"International Journal of Hematology"},{"issue":"5","key":"10291_CR91","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31634","volume":"72","author":"AC Holland","year":"2025","unstructured":"Holland, A. C., Smith, J., Wang, L., Muller, B., & Inaba, H. (2025). Reduced-intensity chemotherapy with immunotherapy for children with Down syndrome and B-cell acute lymphoblastic leukemia. Pediatric Blood & Cancer, 72(5), Article e31634. https:\/\/doi.org\/10.1002\/pbc.31634","journal-title":"Pediatric Blood & Cancer"},{"issue":"5","key":"10291_CR92","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/j.1365-2141.2008.07081.x","volume":"141","author":"T Sato","year":"2008","unstructured":"Sato, T., Toki, T., Kanezaki, R., Xu, G., Terui, K., Kanegane, H., Miura, M., Adachi, S., Migita, M., Morinaga, S., Nakano, T., Endo, M., Kojima, S., Kiyoi, H., Mano, H., & Ito, E. (2008). Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome. British Journal of Haematology, 141(5), 681\u2013688. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07081.x","journal-title":"British Journal of Haematology"},{"key":"10291_CR93","doi-asserted-by":"publisher","unstructured":"Walters, D. K., Mercher, T., Gu, T.-L., O\u2019Hare, T., Tyner, J. W., Loriaux, M., \u2026 Druker, B. J. (2006). Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell, 10(1), 65\u201375. https:\/\/doi.org\/10.1016\/j.ccr.2006.06.002","DOI":"10.1016\/j.ccr.2006.06.002"},{"key":"10291_CR94","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1038\/s41467-019-09917-0","volume":"10","author":"CD Drenberg","year":"2019","unstructured":"Drenberg, C. D., Shelat, A., Dang, J., Cotton, A., Orwick, S. J., Li, M., Jeon, J. Y., Fu, Q., Buelow, D. R., Pioso, M., Hu, S., Inaba, H., Ribeiro, R. C., Rubnitz, J. E., Gruber, T. A., Guy, R. K., & Baker, S. D. (2019). A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. Nature Communications, 10, 2189. https:\/\/doi.org\/10.1038\/s41467-019-09917-0","journal-title":"Nature Communications"},{"issue":"7","key":"10291_CR95","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1038\/s41375-022-01603-3","volume":"36","author":"J Grimm","year":"2022","unstructured":"Grimm, J., Bhayadia, R., Gack, L., Heckl, D., & Klusmann, J.-H. (2022). Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core. Leukemia, 36(7), 1926\u20131930. https:\/\/doi.org\/10.1038\/s41375-022-01603-3","journal-title":"Leukemia"},{"key":"10291_CR96","doi-asserted-by":"publisher","first-page":"101154","DOI":"10.1016\/j.blre.2023.101154","volume":"64","author":"SP Barwe","year":"2024","unstructured":"Barwe, S. P., Kolb, E. A., & Gopalakrishnapillai, A. (2024). Down syndrome and leukemia: An insight into the disease biology and current treatment options. Blood Reviews, 64, 101154. https:\/\/doi.org\/10.1016\/j.blre.2023.101154","journal-title":"Blood Reviews"},{"issue":"7","key":"10291_CR97","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/s41375-023-01937-6","volume":"37","author":"H Issa","year":"2023","unstructured":"Issa, H., Bhayadia, R., Winkler, R., Swart, L. E., Heckl, D., & Klusmann, J.-H. (2023). Preclinical testing of miRNA-193b-3p mimic in acute myeloid leukemias. Leukemia, 37(7), 1583. https:\/\/doi.org\/10.1038\/s41375-023-01937-6","journal-title":"Leukemia"},{"issue":"3","key":"10291_CR98","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/leu.2013.264","volume":"28","author":"MV Stankov","year":"2014","unstructured":"Stankov, M. V., El Khatib, M., Kumar Thakur, B., Heitmann, K., Panayotova-Dimitrova, D., Schoening, J., Bourquin, J. P., Schweitzer, N., Leverkus, M., Welte, K., Reinhardt, D., Li, Z., Orkin, S. H., Behrens, G. M. N., & Klusmann, J. H. (2014). Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. Leukemia, 28(3), 577\u2013588. https:\/\/doi.org\/10.1038\/leu.2013.264","journal-title":"Leukemia"},{"issue":"8","key":"10291_CR99","doi-asserted-by":"publisher","first-page":"e27785","DOI":"10.1002\/pbc.27785","volume":"66","author":"CRM Wiggers","year":"2019","unstructured":"Wiggers, C. R. M., Govers, A. M. A. P., Lelieveld, D., Egan, D. A., Zwaan, C. M., Sonneveld, E., Coffer, P. J., & Bartels, M. (2019). Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia. Pediatric Blood & Cancer, 66(8), e27785. https:\/\/doi.org\/10.1002\/pbc.27785","journal-title":"Pediatric Blood & Cancer"},{"issue":"Supplement_1","key":"10291_CR100","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1182\/blood-2019-131050","volume":"134","author":"S Barwe","year":"2019","unstructured":"Barwe, S., Kolb, E. A., Crowgey, E. L., Druley, T. E., & Gopalakrishnapillai, A. (2019). Generation, characterization and pre-clinical drug evaluation of patient-derived xenograft models of pediatric Down syndrome AML. Blood, 134(Supplement_1), 2683\u20132683. https:\/\/doi.org\/10.1182\/blood-2019-131050","journal-title":"Blood"},{"issue":"Supplement 1","key":"10291_CR101","doi-asserted-by":"publisher","first-page":"5951","DOI":"10.1182\/blood-2022-170549","volume":"140","author":"K Cicek","year":"2022","unstructured":"Cicek, K., Faust, J. R., Tavenner, M., Kolb, E. A., Barwe, S. P., & Gopalakrishnapillai, A. (2022). Preclinical validation of EZH2 and HDAC I dual inhibition as a potent therapy for refractory myeloid leukemia associated with Down syndrome. Blood, 140(Supplement 1), 5951\u20135952. https:\/\/doi.org\/10.1182\/blood-2022-170549","journal-title":"Blood"},{"issue":"12","key":"10291_CR102","doi-asserted-by":"publisher","first-page":"e27414","DOI":"10.1002\/pbc.27414","volume":"65","author":"S Uemura","year":"2018","unstructured":"Uemura, S., Mori, T., Nagano, C., Takafuji, S., Nishimura, N., Toki, T., Terui, K., Ito, E., & Iijima, K. (2018). Effective response to azacitidine in a child with a second relapse of myeloid leukemia associated with Down syndrome after bone marrow transplantation. Pediatric Blood & Cancer, 65(12), e27414. https:\/\/doi.org\/10.1002\/pbc.27414","journal-title":"Pediatric Blood & Cancer"},{"issue":"1","key":"10291_CR103","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1097\/MPH.0000000000001158","volume":"41","author":"K Becktell","year":"2019","unstructured":"Becktell, K., Houser, K., & Burke, M. J. (2019). Epigenetic therapy in a patient with Down syndrome and refractory acute myeloid leukemia. Journal of Pediatric Hematology\/Oncology, 41(1), Article e38. https:\/\/doi.org\/10.1097\/MPH.0000000000001158","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"9","key":"10291_CR104","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1002\/pbc.26062","volume":"63","author":"C Scheer","year":"2016","unstructured":"Scheer, C., Kratz, C., Witt, O., Creutzig, U., Reinhardt, D., & Klusmann, J.-H. (2016). Hematologic response to vorinostat treatment in relapsed myeloid leukemia of Down syndrome. Pediatric Blood & Cancer, 63(9), 1677\u20131679. https:\/\/doi.org\/10.1002\/pbc.26062","journal-title":"Pediatric Blood & Cancer"},{"issue":"5","key":"10291_CR105","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s41375-023-01856-6","volume":"37","author":"N Gossai","year":"2023","unstructured":"Gossai, N., Bhojwani, D., Schafer, E. S., Chang, B. H., Pommert, L., Verma, A., Malvar, J., Chi, Y. Y., Hitzler, J., Burke, M. J., & Rabin, K. R. (2023). Patients with Down syndrome can be included in early phase clinical trials- A report from the T2016\u2013003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study. Leukemia, 37(5), 1138\u20131140. https:\/\/doi.org\/10.1038\/s41375-023-01856-6","journal-title":"Leukemia"},{"key":"10291_CR106","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1182\/blood-2021-154391","volume":"138","author":"SP Barwe","year":"2021","unstructured":"Barwe, S. P., Crowgey, E. L., Zhang, Q., Kolb, E. A., & Gopalakrishnapillai, A. (2021). Bcl2 inhibitor and DNA hypomethylating agent prolong survival in patient-derived xenograft model of Down syndrome myeloid leukemia by synergistic downregulation of cytokine signaling. Blood, 138, 3452. https:\/\/doi.org\/10.1182\/blood-2021-154391","journal-title":"Blood"},{"issue":"Supplement 1","key":"10291_CR107","doi-asserted-by":"publisher","first-page":"8817","DOI":"10.1182\/blood-2022-170441","volume":"140","author":"SP Barwe","year":"2022","unstructured":"Barwe, S. P., Pikman, Y., Kolb, E. A., & Gopalakrishnapillai, A. (2022). Selinexor prolongs survival in patient-derived xenograft models of Down syndrome myeloid leukemia. Blood, 140(Supplement 1), 8817\u20138818. https:\/\/doi.org\/10.1182\/blood-2022-170441","journal-title":"Blood"},{"issue":"7","key":"10291_CR108","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.3390\/jcm11071923","volume":"11","author":"SP Barwe","year":"2022","unstructured":"Barwe, S. P., Huang, F., Kolb, E. A., & Gopalakrishnapillai, A. (2022). Imetelstat induces leukemia stem cell death in pediatric acute myeloid leukemia patient-derived xenografts. Journal of Clinical Medicine, 11(7), 1923. https:\/\/doi.org\/10.3390\/jcm11071923","journal-title":"Journal of Clinical Medicine"},{"issue":"3","key":"10291_CR109","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1172\/JCI60455","volume":"122","author":"S Malinge","year":"2012","unstructured":"Malinge, S., Bliss-Moreau, M., Kirsammer, G., Diebold, L., Chlon, T., Gurbuxani, S., & Crispino, J. D. (2012). Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. The Journal of Clinical Investigation, 122(3), 948\u2013962. https:\/\/doi.org\/10.1172\/JCI60455","journal-title":"The Journal of Clinical Investigation"},{"issue":"10","key":"10291_CR110","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/pbc.25081","volume":"61","author":"JT Caldwell","year":"2014","unstructured":"Caldwell, J. T., Edwards, H., Buck, S. A., Ge, Y., & Taub, J. W. (2014). Targeting the Wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia. Pediatric Blood & Cancer, 61(10), 1767\u20131773. https:\/\/doi.org\/10.1002\/pbc.25081","journal-title":"Pediatric Blood & Cancer"},{"key":"10291_CR111","doi-asserted-by":"publisher","unstructured":"Wen, Q., Goldenson, B., Silver, S. J., Schenone, M., Dancik, V., Huang, Z., \u2026 Crispino, J. D. (2012). Integrative screening approach identifies regulators of polyploidization and targets for acute megakaryocytic leukemia. Cell, 150(3), 575\u2013589. https:\/\/doi.org\/10.1016\/j.cell.2012.06.032","DOI":"10.1016\/j.cell.2012.06.032"},{"issue":"14","key":"10291_CR112","doi-asserted-by":"publisher","first-page":"e156290","DOI":"10.1172\/JCI156290","volume":"132","author":"B Arkoun","year":"2022","unstructured":"Arkoun, B., Robert, E., Boudia, F., Mazzi, S., Dufour, V., Siret, A., Mammasse, Y., Aid, Z., Vieira, M., Aygun, I., Aglave, M., Cambot, M., Petermann, R., Souquere, S., Rameau, P., Catelain, C., Diot, R., Tachdjian, G., Hermine, O., \u2026 Vainchenker, W. (2022). Stepwise GATA1 and SMC3 mutations alter megakaryocyte differentiation in a Down syndrome leukemia model. Journal of Clinical Investigation, 132(14), e156290. https:\/\/doi.org\/10.1172\/JCI156290","journal-title":"Journal of Clinical Investigation"},{"key":"10291_CR113","doi-asserted-by":"publisher","unstructured":"Carey-Smith, S. L., Simad, M. H., Panchal, K., Aya-Bonilla, C., Smolders, H., Lin, S., \u2026 Malinge, S. (2024). Efficacy of DYRK1A inhibitors in novel models of Down syndrome acute lymphoblastic leukemia. Haematologica, 109(7), 2309\u20132315. https:\/\/doi.org\/10.3324\/haematol.2023.284271","DOI":"10.3324\/haematol.2023.284271"},{"issue":"11","key":"10291_CR114","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1038\/leu.2017.93","volume":"31","author":"AM Savino","year":"2017","unstructured":"Savino, A. M., Sarno, J., Trentin, L., Vieri, M., Fazio, G., Bardini, M., Bugarin, C., Fossati, G., Davis, K. L., Gaipa, G., Izraeli, S., Meyer, L. H., Nolan, G. P., Biondi, A., Te Kronnie, G., Palmi, C., & Cazzaniga, G. (2017). The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL. Leukemia, 31(11), 2365\u20132375. https:\/\/doi.org\/10.1038\/leu.2017.93","journal-title":"Leukemia"},{"key":"10291_CR115","doi-asserted-by":"publisher","first-page":"115809","DOI":"10.1016\/j.bcp.2023.115809","volume":"217","author":"A Oikonomou","year":"2023","unstructured":"Oikonomou, A., Valsecchi, L., Quadri, M., Watrin, T., Scharov, K., Procopio, S., Tu, J.-W., Vogt, M., Savino, A. M., Silvestri, D., Valsecchi, M. G., Biondi, A., Borkhardt, A., Bhatia, S., Cazzaniga, G., Fazio, G., Bardini, M., & Palmi, C. (2023). High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor acute lymphoblastic leukemia. Biochemical Pharmacology, 217, 115809. https:\/\/doi.org\/10.1016\/j.bcp.2023.115809","journal-title":"Biochemical Pharmacology"},{"key":"10291_CR116","doi-asserted-by":"publisher","unstructured":"Jones, D., Woods, E., Li, Z., Schaller, K. L., Hoffmeyer, E., Kooiman, B., \u2026 Verneris, M. R. (2024, November 21). Metabolic vulnerabilities in Down syndrome B-cell acute lymphoblastic leukemia can be targeted using Venetoclax. bioRxiv. https:\/\/doi.org\/10.1101\/2024.09.30.615872","DOI":"10.1101\/2024.09.30.615872"},{"issue":"1","key":"10291_CR117","doi-asserted-by":"publisher","first-page":"e70069","DOI":"10.1002\/hem3.70069","volume":"9","author":"FM Hormann","year":"2025","unstructured":"Hormann, F. M., \u00d8stergaard, A., van den Broek, S., Boeree, A., van de Ven, C., Escherich, G., Sonneveld, E., Boer, J. M., & den Boer, M. L. (2025). Secondary lesions and sensitivity to signaling inhibitors in iAMP21 acute lymphoblastic leukemia. HemaSphere, 9(1), e70069. https:\/\/doi.org\/10.1002\/hem3.70069","journal-title":"HemaSphere"},{"issue":"13","key":"10291_CR118","doi-asserted-by":"publisher","first-page":"e34033","DOI":"10.1016\/j.heliyon.2024.e34033","volume":"10","author":"A Oikonomou","year":"2024","unstructured":"Oikonomou, A., Watrin, T., Valsecchi, L., Scharov, K., Savino, A. M., Schliehe-Diecks, J., Bardini, M., Fazio, G., Bresolin, S., Biondi, A., Borkhardt, A., Bhatia, S., Cazzaniga, G., & Palmi, C. (2024). Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening. Heliyon, 10(13), e34033. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34033","journal-title":"Heliyon"},{"issue":"10","key":"10291_CR119","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1242\/dmm.029728","volume":"10","author":"Y Herault","year":"2017","unstructured":"Herault, Y., Delabar, J. M., Fisher, E. M. C., Tybulewicz, V. L. J., Yu, E., & Brault, V. (2017). Rodent models in Down syndrome research: Impact and future opportunities. Disease Models & Mechanisms, 10(10), 1165\u20131186. https:\/\/doi.org\/10.1242\/dmm.029728","journal-title":"Disease Models & Mechanisms"},{"issue":"6","key":"10291_CR120","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/ng.2949","volume":"46","author":"AA Lane","year":"2014","unstructured":"Lane, A. A., Chapuy, B., Lin, C. Y., Tivey, T., Li, H., Townsend, E. C., van Bodegom, D., Day, T. A., Wu, S.-C., Liu, H., Yoda, A., Alexe, G., Schinzel, A. C., Sullivan, T. J., Malinge, S., Taylor, J. E., Stegmaier, K., Jaffe, J. D., Bustin, M., \u2026 Weinstock, D. M. (2014). Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nature Genetics, 46(6), 618\u2013623. https:\/\/doi.org\/10.1038\/ng.2949","journal-title":"Nature Genetics"},{"issue":"6","key":"10291_CR121","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41388-021-02126-4","volume":"41","author":"EC Page","year":"2022","unstructured":"Page, E. C., Heatley, S. L., Eadie, L. N., McClure, B. J., de Bock, C. E., Omari, S., Yeung, D. T., Hughes, T. P., Thomas, P. Q., & White, D. L. (2022). HMGN1 plays a significant role in CRLF2 driven Down syndrome leukemia and provides a potential therapeutic target in this high-risk cohort. Oncogene, 41(6), 797\u2013808. https:\/\/doi.org\/10.1038\/s41388-021-02126-4","journal-title":"Oncogene"},{"key":"10291_CR122","doi-asserted-by":"publisher","DOI":"10.1172\/JCI135937","author":"RS Bhansali","year":"2021","unstructured":"Bhansali, R. S., Rammohan, M., Lee, P., Laurent, A. P., Wen, Q., Suraneni, P., Yip, B. H., Tsai, Y.-C., Jenni, S., Bornhauser, B., Siret, A., Fruit, C., Pacheco-Benichou, A., Harris, E., Besson, T., Thompson, B. J., Goo, Y. A., Hijiya, N., Vilenchik, M., \u2026 Crispino, J. D. (2021). DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3. Journal of Clinical Investigation. https:\/\/doi.org\/10.1172\/JCI135937","journal-title":"Journal of Clinical Investigation"},{"key":"10291_CR123","doi-asserted-by":"publisher","unstructured":"Junco, J. J., Rochette, M., Alozie, M., Rashid, R., Terrell, M., Zorman, B., \u2026 Rabin, K. R. (2024). A transgenic mouse model of Down syndrome acute lymphoblastic leukemia identifies targetable vulnerabilities. Haematologica, 109(12), 4083\u20134088. https:\/\/doi.org\/10.3324\/haematol.2023.284761","DOI":"10.3324\/haematol.2023.284761"},{"key":"10291_CR124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-024-02493-3","volume":"39","author":"T Balestra","year":"2024","unstructured":"Balestra, T., Niswander, L. M., Bagashev, A., Loftus, J. P., Ross, S. L., Chen, R. K., McClellan, Samantha M., Junco, Jacob J., B\u00e1rcenas L\u00f3pez, Diego A., Rabin, Karen R.., Fry, Terry J., & Tasian, S. K. (2024). Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia. Leukemia, 39, 1. https:\/\/doi.org\/10.1038\/s41375-024-02493-3","journal-title":"Leukemia"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-025-10291-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-025-10291-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-025-10291-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T11:59:09Z","timestamp":1758196749000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-025-10291-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":124,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10291"],"URL":"https:\/\/doi.org\/10.1007\/s10555-025-10291-1","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RSK discloses advisory board participation for Jazz Pharmaceuticals, Amgen and Link Healthcare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}